Pharma
AstraZeneca taps insitro's AI platform in a $40 million upfront deal for MASH and heart-muscle diseases
Insitro will apply its Virtual Human AI platform to MASH and cardiomyopathies. AstraZeneca will run clinical development and keep exclusive worldwide rights to selected programmes.
